Executive Medical Director, Clinical Leader- Neuroscience; Early Development & Experimental Med

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and Med Tech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at

Discovery & Pre-Clinical/Clinical Development

Clinical Development & Research – MD

Scientific/Technology

Cambridge, Massachusetts, United States of America;

Raritan, New Jersey, United States of America;

Spring House, Pennsylvania, United States of America;

Titusville, New Jersey, United States of America;

Johnson & Johnson is recruiting for an Executive Medical Director, Clinical Leader - Neuroscience Early Development & Experimental Medicine to be located in Raritan, NJ, Titusville, NJ, Cambridge, MA or Spring House, PA. Remote work options may be considered on a case-by-case basis and if approved by the Company.

Our expertise in Innovative Medicine is informed and inspired by patients, whose insights fuel our science-based advancements. Visionaries like you work on teams that save lives by developing the medicines of tomorrow.

Our Neuroscience team tackles the world’s toughest brain health challenges including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, myasthenia gravis, epilepsy, major depressive disorder, bipolar disorder, schizophrenia, and autism. This patient-focused team helps address some of the most complex diseases of our time.

Join us in developing treatments, finding cures, and pioneering the path from lab to life while championing patients every step of the way.

Learn more at

The Clinical Leader for Neuroscience Early Development & Experimental Medicine will serve as the clinical lead for multiple early‑stage programs in Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative indications. This role will be accountable for shaping the clinical strategy, designing and overseeing early‑phase clinical studies, and driving programs from first‑in‑human through Proof‑of‑Concept.

The role requires deep scientific and clinical expertise in neuroscience, strong leadership in cross‑functional drug development, and the ability to operate in an innovation‑focused environment. The Director/Executive Director will partner closely with discovery, translational science, biomarkers, clinical pharmacology, biostatistics, regulatory, and external academic collaborators to advance transformative therapies for patients.

• Develop and lead clinical development strategies from IND/CTA through Phase I and Phase IIa Proof‑of‑Concept/Proof‑of-Mechanism.
• Integrate translational hypotheses, biomarker strategies, precision measures (for patient selection, pharmacodynamic measures) and patient‑centric approaches into clinical plans.
• Ensure scientific rigor, clinical feasibility, and regulatory alignment in all development strategies.
• Lead the design of innovative and lean signal seeking early‑phase clinical trials, including adaptive and biomarker‑enriched designs.
• Provide clinical oversight for study execution, including safety monitoring, dose selection, protocol amendments, and data interpretation.
• Lead cross‑functional clinical study teams and work closely with biomarker, PK/PD, biostatistics, and operations teams to ensure high‑quality clinical execution.
• Be a core member of the early development compound team for specific assets. Guide decision‑making at project milestones and participate in governance reviews.
• Engage with regulatory affairs to inform early interactions with FDA, EMA, and other agencies.
• Establish and maintain relationships with global key opinion leaders, academic partners, and clinical investigators.
• Represent the company at scientific meetings, advisory boards, and consortiums in neuroscience and neurodegeneration.
• Contributes to in‑licensing evaluations and…